Ghaffari Reza, Barijani Sahar, Alivand Arash, Latifi Golshan, Ghassemi Hamed, Zarei-Ghanavati Mehran, Djalilian Ali R
Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.
J Curr Ophthalmol. 2021 Oct 22;33(3):260-265. doi: 10.4103/2452-2325.329089. eCollection 2021 Jul-Sep.
To investigate the effects of topical and perilesional interferon alpha-2b as primary treatment for ocular surface squamous neoplasia (OSSN).
In this prospective interventional case series, topical interferon alpha-2b (3 MIU/mL) was used as the initial treatment of OSSN, with perilesional interferon alpha-2b (3 MIU/mL) added based on clinical response. The primary outcome was complete tumor resolution. Spearman's rank correlation test was used to investigate the association of complete tumor resolution and time to resolution with baseline tumor characteristics and the American Joint Committee on Cancer (AJCC) classification for OSSN.
Ninety-two patients (92 OSSN tumors) were included in the study. The total follow-up duration was 13.57 ± 2.14 months (median: 12, range: 3-23). The median basal tumor diameter was 4 mm (mean: 4.13 ± 1.37). Complete tumor resolution was achieved in 89 cases (96.73%), with a median time to complete tumor resolution of 5 months (mean: 4.64 ± 1.92). Complete tumor resolution was 57 of 57 in T1 (100%), 8 of 9 in T2 (88.88%), and 21 of 23 in T3 (91.30%). There were statistically significant correlations between AJCC classification and complete tumor resolution (Spearman's = -0.22, = 0.03) and maximal basal tumor diameter and the time to complete resolution (Spearman's = 0.35, = 0.001). There were no recurrences during the study follow-up period.
Topical interferon alpha-2b is effective and well tolerated as a primary treatment for OSSN, with a high rate of tumors responding completely to therapy.
探讨局部及病变周围注射干扰素α-2b作为眼表鳞状上皮肿瘤（OSSN）初始治疗的效果。
在这个前瞻性干预性病例系列研究中，局部应用干扰素α-2b（3 MIU/mL）作为OSSN的初始治疗，并根据临床反应在病变周围注射干扰素α-2b（3 MIU/mL）。主要结局为肿瘤完全消退。采用Spearman等级相关检验来研究肿瘤完全消退及消退时间与基线肿瘤特征和美国癌症联合委员会（AJCC）对OSSN的分类之间的关联。
92例患者（92个OSSN肿瘤）纳入研究。总随访时间为13.57±2.14个月（中位数：12个月，范围：3 - 23个月）。肿瘤基底直径中位数为4 mm（平均值：4.13±1.37）。89例（96.73%）实现了肿瘤完全消退，肿瘤完全消退的中位时间为5个月（平均值：4.64±1.92）。T1期57例中有57例（100%）完全消退，T2期9例中有8例（88.88%）完全消退，T3期23例中有21例（91.30%）完全消退。AJCC分类与肿瘤完全消退之间存在统计学显著相关性（Spearman相关系数 = -0.22，P = 0.03），最大基底肿瘤直径与完全消退时间之间也存在统计学显著相关性（Spearman相关系数 = 0.35，P = 0.001）。研究随访期间无复发。
局部应用干扰素α-2b作为OSSN的初始治疗有效且耐受性良好，肿瘤对治疗的完全缓解率高。
